News

Every respiratory season, healthcare providers across the United States face the same operational challenge: a high volume of patients presenting similar respiratory symptoms with limited time to make accurate clinical decisions.

Fever, cough, congestion, fatigue, and body aches can be associated with Influenza A, Influenza B, or COVID-19, making symptom-based diagnosis unreliable. As a result, U.S. clinics and laboratories increasingly rely on rapid diagnostic testing to maintain efficiency and quality of care.

---

The diagnostic challenge during respiratory season

For clinics, urgent care centers, and laboratories, respiratory season is not only a clinical challenge—it is an operational one.

Relying on separate tests for each pathogen can lead to:

• Longer patient wait times
• Increased use of clinical resources
• Higher inventory complexity
• Reduced staff efficiency

These challenges have driven demand for combined Influenza and COVID-19 diagnostic testing, especially in point-of-care environments.

---

Why Influenza testing remains critical in the U.S.

Despite changing public perception, Influenza continues to be a major driver of seasonal healthcare demand in the United States. Each year, Influenza A and B account for millions of outpatient visits, urgent care consultations, and diagnostic tests nationwide.

Healthcare providers that prepare for Influenza season in advance are better positioned to:

• Maintain consistent patient flow
• Reduce unnecessary follow-up visits
• Support faster treatment decisions

Influenza testing remains a core component of respiratory care strategies across the U.S. healthcare system.

---

The shift toward Influenza + COVID-19 combination testing

Over the last few years, U.S. healthcare buyers have shown a clear preference for diagnostic solutions that detect multiple respiratory pathogens in a single test.

Combined Influenza A/B and COVID-19 tests are valued for their ability to:

• Deliver rapid, actionable results
• Streamline clinical workflows
• Minimize inventory and storage requirements
• Improve patient throughput during peak periods

For high-volume clinics and urgent care centers, combination testing has become a practical standard rather than an exception.

---

Who uses combined respiratory diagnostic tests?

In the United States, combined Influenza and COVID-19 tests are commonly utilized by:

• Private medical clinics
• Urgent care centers
• Diagnostic laboratories
• Occupational health providers
• Employer health programs
• Medical distributors and healthcare networks

These tests are designed for professional use, not direct-to-consumer retail, and are typically purchased through B2B procurement channels.

---

B2B purchasing considerations in the U.S. healthcare market

Unlike consumer medical products, diagnostic tests for professional use are evaluated based on:

• Operational efficiency

• Seasonal demand planning

• Regulatory compliance

• Volume availability

• Supplier reliability

Healthcare organizations often prioritize partners who provide clear technical information, consistent supply, and scalable purchasing options, especially ahead of respiratory season.

---

Planning ahead makes a measurable difference

U.S. clinics and laboratories that secure diagnostic testing solutions before peak respiratory season benefit from:

• Reduced risk of supply shortages

• More predictable operating costs

• Faster response during demand spikes

• Improved continuity of patient care

Advance planning is a key factor in maintaining stability during high-demand periods.

---

Information for institutional buyers

Influenza and COVID-19 combination tests are typically offered through institutional sales models, where pricing, availability, and logistics are tailored to healthcare providers and distributors.

For clinics, laboratories, or healthcare organizations evaluating diagnostic options for the upcoming respiratory season, early access to product information can support more informed purchasing decisions.